Finalist for 2nd National Award for SSI reduction

Ondine Biomedical Inc.

23 December 2025

 

23 December 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Finalist for 2nd National Award for SSI reduction

 Ondine and Mid Yorkshire Teaching NHS Trust shortlisted for Excellence in Healthcare Partnership Award for Reducing Surgical Site Infections with Nasal Photodisinfection

Second national award shortlist recognises successful partnership addressing the NHS priority of reducing surgical site infections and antimicrobial resistance.

Ondine Biomedical Inc (AIM: OBI) and Mid Yorkshire Teaching NHS Trust (Mid Yorks) are finalists for the 'Partnership Working to Address National Healthcare Priorities (Local Projects)' category at the prestigious 2026 Excellence in Healthcare Partnership (EHP) Awards.

This shortlisting recognises the successful collaboration between Ondine and Mid Yorks to address one of the NHS's most pressing challenges: reducing surgical site infections (SSIs) while limiting reliance on antibiotics. It follows the Trust's introduction of Ondine's Steriwave^® nasal photodisinfection technology into orthopaedic surgery pathways at its Pontefract and Pinderfields hospitals.

This is the partnership's second recent selection for a national awards shortlist, underscoring nasal photodisinfection as an important infection-prevention and cost-saving approach for the NHS which can help address wait lists, currently exceeding six million patients. This recognition comes on the heels of being named a finalist for the HSJ Partnership Award in the category of 'Most Impactful Use of Technology on Clinical Practice'.  

Implemented for patients undergoing hip and knee replacement surgery at Mid Yorks' Pontefract and Pinderfields hospitals, the Steriwave intervention was associated with a 71% reduction in post-surgical infections in hip surgery over six months, with no SSIs observed in knee surgery during the evaluation period. In addition to improving patient outcomes, the initiative delivered meaningful cost savings by reducing avoidable complications and associated hospital resource use.

The EHP Awards specifically celebrate collaborations that align with national healthcare priorities, including patient safety, antimicrobial stewardship and system efficiency. The Ondine-Mid Yorks partnership demonstrates how clinically integrated innovation can deliver measurable benefits at a local level while supporting broader NHS goals.

Since the initial pilot, Steriwave is now being used or evaluated by several major hospitals across England in a range of surgical specialties, as well as in intensive care, where immunocompromised patients are particularly vulnerable to infection. Adoption has been driven in part by growing concern over mupirocin resistance and poor patient compliance, which limit the effectiveness of antibiotic-based nasal decolonisation.

Unlike antibiotics, photodisinfection rapidly destroys bacteria, viruses and fungi without generating resistance, offering an effective, non-antibiotic approach to infection prevention.

Carolyn Cross, CEO of Ondine, commented:

"This second recent shortlisting for a national award serves as a powerful endorsement, highlighting the recognition of tangible solutions for reducing surgical site infections. It clearly demonstrates what is possible when NHS clinicians and industry partners collaborate to bring innovative approaches to the real-world challenges facing our overstretched healthcare system. Preventing surgical site infections is absolutely vital-not only for patient safety, but also for driving hospital efficiency and supporting antimicrobial stewardship."

Dr Stuart Bond, Consultant Antimicrobial Pharmacist and Director of Innovation at Mid Yorkshire Teaching NHS Trust, added:

"Being shortlisted again reflects both the strength of this collaboration and the value of introducing new approaches that genuinely improve patient care. Patient safety is at the heart of everything we do, and we are proud to be recognised again at a national level for the introduction of photodisinfection."

For healthcare providers in the UK interested in Steriwave^®, the technology is available through Ondine's distribution partner, Mölnlycke Health Care, a global leader in medical solutions. For more information contact: Healthcare Professionals Contact or [e-mail], or call [phone].

About Steriwave^® Nasal Photodisinfection

Steriwave nasal photodisinfection is a non-invasive and painless treatment that uses a proprietary light-activated photosensitive agent to destroy harmful bacteria, viruses, and fungi-including antibiotic-resistant strains-in the nasal passages. The procedure takes five minutes and, unlike antibiotics, is effective immediately and allows the normal nasal microbiome to recover quickly, without fostering antimicrobial resistance, offering a powerful tool in the fight against healthcare-associated infections.

About Excellence in Healthcare Partnership Awards

The Excellence in Healthcare Partnership Awards are organised by PMGroup Worldwide Ltd and Visions4Health and are among the most respected honours recognising collaborations between the NHS and its commercial partners that deliver measurable improvements in patient care, efficiency and value. Recognition at the EHP Awards highlights the strength and effectiveness of a partnership and raises its profile across the NHS and beyond, reinforcing the credibility and impact of the work being celebrated. Winners will be announced at the awards ceremony on 5 February 2026.

Enquiries:

Ondine Biomedical Inc.	www.ondinebio.com
Carolyn Cross, CEO	[phone] or via Vane Percy & Roberts
Strand Hanson Limited (Nominated & Joint Financial Adviser)
James Harris, Richard Johnson	[phone]
Peel Hunt LLP (Broker & Joint Financial Adviser)
James Steel, Dr. Chris Golden	[phone]
Vane Percy & Roberts (Media Contact)
Simon Vane Percy	[phone]

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system is CE-marked in Europe and is approved for nasal decolonisation in Canada, Australia, Mexico and several other countries under the name Steriwave^®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.

About Mölnlycke Health Care 

Mölnlycke Health Care is a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures. Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, Mölnlycke is owned by Investor AB and headquartered in Sweden. www.molnlycke.com 

 

END